A woman has taken to the internet to share the biggest difference she experienced when switching between GLP-1 drugs Wegovy ...

Eli Lilly raised its full-year profit and revenue forecast on Thursday as strong appetite for its widely popular weight-loss ...

Lilly tops Q3 estimates as Mounjaro and Zepbound fuel a 54% revenue surge, prompting the drugmaker to raise its full-year ...

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish ...

Eli Lilly reported higher profit and raised its outlook on surging demand for its weight-loss drugs, sending its shares ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Shares of the world's largest healthcare company by market value were up nearly 2% in morning trading even as investors remain wary of drug price negotiations with the Trump administration.

Through an exclusive partnership with Eli Lilly, the company has begun distributing and promoting Yurpeak (Tirzepatide) in ...

The company sees no supply constraints for tirzepatide, a concern that has plagued other players in the GLP-1 space globally.